CW Advisors LLC Purchases 5,902 Shares of Boston Scientific Corporation $BSX

Key Points

• CW Advisors LLC increased its holdings in Boston Scientific Corporation (BSX) by 2.5%, now owning 241,289 shares valued at approximately $24.3 million.
• Institutional investors have shown strong interest in Boston Scientific, with 89.07% of the stock owned by hedge funds or other institutional investors.
• Boston Scientific's recent quarterly earnings exceeded expectations, reporting $0.75 EPS compared to the consensus estimate of $0.72, reflecting a 22.8% year-over-year revenue growth.

CW Advisors LLC grew its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 2.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 241,289 shares of the medical equipment provider's stock after acquiring an additional 5,902 shares during the period. CW Advisors LLC's holdings in Boston Scientific were worth $24,344,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its position in Boston Scientific by 2.5% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock worth $1,992,994,000 after acquiring an additional 554,388 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock worth $1,677,124,000 after purchasing an additional 834,274 shares during the period. Northern Trust Corp increased its holdings in shares of Boston Scientific by 18.0% during the fourth quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock worth $1,303,681,000 after purchasing an additional 2,221,790 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the business's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 56,372 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $102.88, for a total transaction of $5,799,551.36. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,347,824.96. This represents a 24.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 345,029 shares of company stock valued at $35,976,603 over the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Shares of NYSE BSX traded down $0.99 during midday trading on Monday, reaching $105.18. 4,484,265 shares of the company were exchanged, compared to its average volume of 7,549,425. The stock's 50-day moving average price is $104.10 and its 200-day moving average price is $102.12. The stock has a market cap of $155.85 billion, a P/E ratio of 62.61, a PEG ratio of 2.56 and a beta of 0.66. Boston Scientific Corporation has a one year low of $78.90 and a one year high of $108.94. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. Robert W. Baird raised their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. UBS Group raised their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, Oppenheimer raised their target price on shares of Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.